Compass Therapeutics Inc. (CMPX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Compass Therapeutics Inc. (CMPX) has a cash flow conversion efficiency ratio of -0.093x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-17.27 Million) by net assets ($186.47 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CMPX equity financing ratio to measure how much of total assets are equity-financed.
Compass Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Compass Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Compass Therapeutics Inc. cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Compass Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Compass Therapeutics Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gray Television Inc
NYSE:GTN
|
0.005x |
|
Ningbo Fangzheng Automobile Mould Co.Ltd.
SHE:300998
|
0.023x |
|
Jinhong Fashion Group Co Ltd
SHG:603518
|
-0.014x |
|
Changzhou Almaden Co Ltd
SHE:002623
|
-0.017x |
|
ROX Resources Ltd
AU:RXL
|
-0.149x |
|
Siamgas and Petrochemicals Public Company Limited
BK:SGP-R
|
0.054x |
|
Ashoka Buildcon Limited
NSE:ASHOKA
|
0.099x |
|
Andes Technology Corp
TW:6533
|
-0.006x |
Annual Cash Flow Conversion Efficiency for Compass Therapeutics Inc. (2018–2025)
The table below shows the annual cash flow conversion efficiency of Compass Therapeutics Inc. from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Compass Therapeutics Inc. stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $196.79 Million | $-49.14 Million | -0.250x | +30.28% |
| 2024-12-31 | $125.23 Million | $-44.85 Million | -0.358x | -30.98% |
| 2023-12-31 | $148.54 Million | $-40.62 Million | -0.273x | -45.55% |
| 2022-12-31 | $181.64 Million | $-34.12 Million | -0.188x | -33.82% |
| 2021-12-31 | $140.08 Million | $-19.67 Million | -0.140x | +79.08% |
| 2020-12-31 | $39.95 Million | $-26.80 Million | -0.671x | -350.72% |
| 2019-12-31 | $-118.60 Million | $-31.74 Million | 0.268x | -32.64% |
| 2018-12-31 | $-84.77 Million | $-33.68 Million | 0.397x | -- |
About Compass Therapeutics Inc.
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tum… Read more